曼恩凯德生物医疗 MNKD 深 沪
交易中 10-16 11:53:26 美东时间
3.105
-0.085
-2.66%
华盛通- 最 高3.24
- 今 开3.20
- 成交量 43.46万股
- 最 低 3.10
- 昨 收 3.19
- 总市值 9.98亿
- 52周最高 6.51
- 市盈率 静 166.04
- 换手率 0.14%
- 52周最低 2.23
- 委 比 42.38%
- 总股本 3.22亿
- 历史最高 57.40
- 量 比 0.27
- 振 幅 4.39%
- 历史最低 0.666
- 每 手 1
- 风险率 1.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Truist Securities Maintains Buy on MannKind, Lowers Price Target to $5
Truist Securities analyst Gregory Renza maintains MannKind (NASDAQ:MNKD) with a Buy and lowers the price target from $6 to $5.
10-08 00:51
美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $8 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates MannKind (NASDAQ:MNKD) with a Overweight and maintains $8 price target.
09-11 19:07
MannKind, Rose Pharma team up for inhaled GLP-1 therapy
MannKind Corporation (MNKD) has reached a global licensing and collaboration agreement with Delaware-based Rose Pharma to develop an inhaled GLP-1 therapy designed as a flexible, rapid-acting option f...
09-09 19:12
MannKind And Rose Pharma Enter Into Worldwide Licensing And Collaboration Agreement To Develop ROSE-010 Technosphere For Weight Management
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase...
09-09 18:32
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MannKind Corporation and Rose Pharma Inc. have entered a global licensing agreement to develop ROSE-010 Technosphere for weight management. ROSE-010, a rapid-acting GLP-1 receptor agonist, will be formulated using MannKind's Technosphere inhalation technology. MannKind will receive an equity stake, potential royalties, and a board seat, while providing development and manufacturing support through Phase 1b. Rose Pharma retains clinical and commer...
09-09 10:30
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Wells Fargo Maintains Overweight on MannKind, Lowers Price Target to $13
Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lowers the price target from $14 to $13.
08-07 01:17
MannKind 2026年第二季度财报：营收增43%，费用扩张转为亏损
MannKind 2026年第二季度营收1.094亿美元，同比增长43%，稀释每股亏损0.06美元、净亏损1903万美元；Furoscix与合作收入推动增长，但商业化及融资成本加重亏损。
08-05 21:17
